Alane Koki
- Pharmacology top 0.05%
- Inflammatory mediators and NSAID effects 31
- Drug-Induced Adverse Reactions 2
- Pharmacogenetics and Drug Metabolism 2
- Biochemistry top 0.5%
- Eicosanoids and Hypertension Pharmacology 6
- Genetics top 0.5%
- Estrogen and related hormone effects 20
- Cancer Research top 2%
- NF-κB Signaling Pathways 2
- Psychiatry and Mental health top 1%
- Cancer, Stress, Anesthesia, and Immune Response 12
-
- Radiopharmaceutical Chemistry and Applications 2
- Co-authors
- Jaime L. MasferrerB. Mark WoernerK. LeahyAndrew J. DannenbergKaren SeibertRobert A. SoslowBen S. ZweifelKanwar Nasir M. Khan
- Cited by
- PharmacologyBiochemistryGenetics
- Journals
- Molecular Carcinogenesis (2 papers)Advances in experimental medicine and biology (2 papers)Oncogene (2 papers)
- Partner nations
- United StatesFranceCanada
In The Last Decade
Alane Koki
38 papers receiving 6.0k citations
Hit Papers
Peers
Comparison fields: 5 of 123
- Pharmacology 3.8k
- Biochemistry 639
- Genetics 2.2k
- Cancer Research 1.1k
- Psychiatry and Mental health 1.0k
Countries citing papers authored by Alane Koki
This map shows the geographic impact of Alane Koki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alane Koki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alane Koki more than expected).
Fields of papers citing papers by Alane Koki
This network shows the impact of papers produced by Alane Koki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alane Koki. The network helps show where Alane Koki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Alane Koki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 174 | |
| 2 | 2004 | 2 | |
| 3 | 2004 | 7 | |
| 4 | 2004 | 101 | |
| 5 | 2004 | 18 | |
| 6 | 2003 | 41 | |
| 7 | 2003 | 136 | |
| 8 | 2003 | 1 | |
| 9 | Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. | 2002 | 60 |
| 10 | 2002 | 35 | |
| 11 | 2002 | 42 | |
| 12 | 2002 | 117 | |
| 13 | 2002 | 268 | |
| 14 | 2001 | 60 | |
| 15 | 2000 | 48 | |
| 16 | COX-2 is expressed in human pulmonary, colonic, and mammary tumorsbreakdown → | 2000 | 745 |
| 17 | 2000 | 158 | |
| 18 | 1999 | 99 | |
| 19 | 1999 | 3 | |
| 20 | 1999 | 14 |
About Alane Koki
Alane Koki is a scholar working on Pharmacology, Biochemistry and Psychiatry and Mental health, having authored 38 papers that have together received 6.2k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (31 papers), Estrogen and related hormone effects (20 papers), Cancer, Stress, Anesthesia, and Immune Response (12 papers), Eicosanoids and Hypertension Pharmacology (6 papers), Radiopharmaceutical Chemistry and Applications (2 papers), Drug-Induced Adverse Reactions (2 papers), Pharmacogenetics and Drug Metabolism (2 papers) and NF-κB Signaling Pathways (2 papers). The work is most often cited by research in Pharmacology (3.8k citations), Biochemistry (639 citations) and Genetics (2.2k citations). Alane Koki has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Jaime L. Masferrer, B. Mark Woerner, K. Leahy, Andrew J. Dannenberg, Karen Seibert, Robert A. Soslow, Ben S. Zweifel, Kanwar Nasir M. Khan, D A Edwards and Steven L. Settle. Their work appears in journals such as Molecular Carcinogenesis, Advances in experimental medicine and biology, Oncogene, Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.